On-Demand 3D Bioprinting Company with Award-Winning Team | Developed Patented Materials and Proprietary Technology

“A.D.A.M. presents the first-ever opportunity to print organic bones. The key reason for launching this project is to help people save their lives.

The global 3D bioprinting market is growing rapidly. According to research, it will develop very intensively up to 2024 and achieve more than $2.5B. We strongly believe in the potential of our team, which has launched successful 3D printing projects that have gained a lot of attention.

We hope that A.D.A.M. can bring this innovative endeavour to the next level.”   

Denys Gurak, CEO & Co-Founder, A.D.A.M. Project

Register Interest

Executive Summary

A.D.A.M. (Advanced Development of Additive Manufacturing) provides on-demand 3D bioprinting services. The company uses its proprietary 3D printing technology and patented materials to manufacture bio-resorbable patient-specific implants, primarily bone implants.

A.D.A.M. currently focuses on orthopaedic implants. In the future, it intends to expand its product offerings to cover major blood vessels, heart valves, and bronchial implants.

With the company’s significant achievements over the last two years, the support received from experts on both the scientific and business sides of the project, and the positive response from the FDA, the company anticipates a relatively short and straightforward path to market approval.

Investment Highlights

• 3D-printed implant market in 2019: $1.12B. Projected market in 2027: $3.97B.
• The FDA’s positive response to A.D.A.M.’s Q-submission regarding 510(k) eligibility means that no human trials are required. There will be a decrease in the time to market from 5 years to 1.5-2 years, indicating a straightforward and streamlined regulatory process.
• A.D.A.M.’s implants are less expensive to produce than titanium implants and other alternatives. This cost efficiency creates an economic moat that directly benefits all stakeholders, including patients, insurance companies, hospitals, and investors.
• The Technology Incubation Program at the University of Connecticut has accepted A.D.A.M. and has provided access to its state-of-the-art research facilities and resources.

Investment Offering

A.D.A.M. is raising a maximum round size of $6M for its Series A preferred stock financing.

The company has already secured a lead investor for part of the round.

The Series A round will be closing on 31 July 2021.

Register Interest